Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
NCT00801242
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Degarelix 240 mg / 80 mg
Sponsor
Ferring Pharmaceuticals